The medicine known commercially as Gleevec serves as a powerful weapon for people fighting the blood cancer called chronic myelogenous leukemia, or CML. Although the drug appears to cure many patients, it usually provides only fleeting improvement for those who have entered the crisis stage of the lethal disease.
A new finding could help scientists patch this weakness in the drug's otherwise potent assault on CML. In an upcoming issue of Science, researchers at the University of California, Los Angeles (UCLA) reveal how this cancer rebounds.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.